Agenus (NASDAQ:AGEN) Price Target Lowered to $3.00 at Robert W. Baird

Agenus (NASDAQ:AGEN) had its target price reduced by Robert W. Baird from $6.00 to $3.00 in a report issued on Wednesday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research report on Wednesday. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.75.

Agenus Price Performance

AGEN opened at $1.87 on Wednesday. The stock has a 50-day moving average price of $3.23 and a 200-day moving average price of $3.84. The firm has a market cap of $43.87 million, a PE ratio of -0.17 and a beta of 1.23. Agenus has a 1 year low of $1.86 and a 1 year high of $19.69.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. As a group, sell-side analysts anticipate that Agenus will post -12.55 EPS for the current year.

Institutional Investors Weigh In On Agenus

Several large investors have recently bought and sold shares of the business. Barclays PLC increased its holdings in Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after buying an additional 4,924 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares during the last quarter. State Street Corp increased its position in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Agenus during the 3rd quarter valued at about $55,000. Finally, Point72 DIFC Ltd increased its position in shares of Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 11,542 shares during the last quarter. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.